| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 1
Mitragyna inermis (Willd.) O. Kuntze ethnopharmacology and metabolic disorders: An update review and in silico study
1 Nazi BONI University, Laboratory of Research and Teaching in Animal Health and Biotechnologies, Bobo-Dioulasso, Burkina Faso2 Karachi University, H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, Karachi, Pakistan
3 Nazi BONI University, Department of Biochemistry-Microbiology, Life and Earth Sciences Training and Research Unit, Bobo-Dioulasso, Burkina Faso
4 Karachi University, International Center for Chemical and Biological Sciences, Dr. Panjwani Center for Molecular Medicine and Drug Research, Karachi, Pakistan
DOI : 10.23893/1307-2080.APS6302 Viewed : 81 - Downloaded : 42 Mitragyna inermis is a wild plant whose parts are traditionally used. However, there is no particular report on the compounds bioactivity evidence against metabolic disorders. We carried out a literature review of this plant uses and compounds mostly isolated in diabetic and hypertensive states. Following the review, we carried out an in silico study on major targets for research into antidiabetic and antihypertensive candidates. From this study, it emerged that the plant is used in the treatment of diabetes and hypertension. The main compounds isolated from this plant were terpenoids and alkaloids. The in silico study revealed that these compounds could inhibit ?-amylase, ?-glucosidase and sodium glucose co-transporter 2 in diabetic status, as well as angiotensin converting enzyme in hypertensive status. Most of these compounds could be absorbed and metabolized on the basis of ADME (Adsorption, Distribution, Metabolism and Excretion) pharmacokinetic prediction. Further studies are needed to optimize its activities and conduct in vitro trials. Keywords : Mitragyna inermis, metabolic disorders, in silico study, diabetes, hypertension